(Circulation. 1999;99:2440-2444.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Role of Plasminogen System Components in Focal Cerebral Ischemic Infarction
A Gene Targeting and Gene Transfer Study in Mice
From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology (N.N., P.C.), and the Center for Molecular and Vascular Biology (M.D.M., H.R.L., D.C.), KU Leuven, Belgium, and the Department of Physiology, Hamamatsu University School of Medicine, Shizuoka, Japan (N.N.).
Correspondence to Désiré Collen, MD, PhD, Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Campus Gasthuisberg, B-3000 Leuven, Belgium. E-mail desire.collen{at}med.kuleuven.ac.be
Background—The role of
plasminogen system components in focal cerebral
ischemic infarction (FCI) was studied in mice deficient in
plasminogen (Plg-/-), in tissue or urokinase
plasminogen activator (tPA-/- or
uPA-/-), or in plasminogen
activator inhibitor-1 or
2-antiplasmin (PAI-1-/- or
2-AP-/-).
Methods and Results—FCI was produced by ligation of the left
middle cerebral artery and measured after 24 hours by planimetry of
stained brain slices. In control (wild-type) mice, infarct size was
7.6±1.1 mm3 (mean±SEM), uPA-/- mice
had similar infarcts (7.8±1.0 mm3,
P=NS), tPA-/- mice smaller (2.6±0.80
mm3, P<0.0001), PAI-1-/- mice
larger (16±0.52 mm3, P<0.0001), and
Plg-/- mice larger (12±1.2 mm3,
P=0.037) infarcts. 2-AP-/-
mice had smaller infarcts (2.2±1.1 mm3,
P<0.0001 versus wild-type), which increased to
13±2.5 mm3 (P<0.005 versus
2-AP-/-) after intravenous
injection of human 2-AP. Injection into
2-AP-/- mice of Fab fragments of
affinospecific rabbit IgG against human 2-AP, after
injection of 200 µg human 2-AP, reduced FCI from
11±1.5 to 5.1±1.1 mm3 (P=0.004).
Conclusions—Plg system components affect FCI at 2 different
levels: (1) reduction of tPA activity (tPA gene
inactivation) reduces whereas its augmentation (PAI-1
gene inactivation) increases infarct size, and (2) reduction of Plg
activity (Plg gene inactivation or 2-AP
injection) increases whereas its augmentation
(2-AP gene inactivation or
2-AP neutralization) reduces infarct size. Inhibition of
2-AP may constitute a potential avenue to treatment
of FCI.
Key Words: plasminogen • plasminogen activators • cerebral infarction • cerebral ischemia
This article has been cited by other articles:
 |
|
 |
|
  F. Adhami, D. Yu, W. Yin, A. Schloemer, K. A. Burns, G. Liao, J. L. Degen, J. Chen, and C.-Y. Kuan Deleterious Effects of Plasminogen Activators in Neonatal Cerebral Hypoxia-Ischemia Am. J. Pathol., June 1, 2008; 172(6): 1704 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Polavarapu, J. An, C. Zhang, and M. Yepes Regulated Intramembrane Proteolysis of the Low-Density Lipoprotein Receptor-Related Protein Mediates Ischemic Cell Death Am. J. Pathol., May 1, 2008; 172(5): 1355 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Ozog, G. Modha, J. Church, R. Reilly, and C. C. Naus Co-administration of Ciliary Neurotrophic Factor with Its Soluble Receptor Protects against Neuronal Death and Enhances Neurite Outgrowth J. Biol. Chem., March 7, 2008; 283(10): 6546 - 6560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Orset, R. Macrez, A. R. Young, D. Panthou, E. Angles-Cano, E. Maubert, V. Agin, and D. Vivien Mouse Model of In Situ Thromboembolic Stroke and Reperfusion Stroke, October 1, 2007; 38(10): 2771 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, R. Polavarapu, H. She, Z. Mao, and M. Yepes Tissue-Type Plasminogen Activator and the Low-Density Lipoprotein Receptor-Related Protein Mediate Cerebral Ischemia-Induced Nuclear Factor-{kappa}B Pathway Activation Am. J. Pathol., October 1, 2007; 171(4): 1281 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Polavarapu, M. C. Gongora, H. Yi, S. Ranganthan, D. A. Lawrence, D. Strickland, and M. Yepes Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit Blood, April 15, 2007; 109(8): 3270 - 3278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Benchenane, H. Castel, M. Boulouard, R. Bluthe, M. Fernandez-Monreal, B. D. Roussel, J. P. Lopez-Atalaya, S. Butt-Gueulle, V. Agin, E. Maubert, et al. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory J. Cell Sci., February 15, 2007; 120(4): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Akkawi, T. Nassar, M. Tarshis, D. B. Cines, and A. A.-R. Higazi LRP and {alpha}vbeta3 mediate tPA activation of smooth muscle cells Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1351 - H1359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Polavarapu, M. C. Gongora, J. A. Winkles, and M. Yepes Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Increases the Permeability of the Neurovascular Unit through Nuclear Factor-{kappa}B Pathway Activation J. Neurosci., November 2, 2005; 25(44): 10094 - 10100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Reddrop, R. X. Moldrich, P. M. Beart, M. Farso, G. T. Liberatore, D. W. Howells, K.-U. Petersen, W.-D. Schleuning, and R. L. Medcalf Vampire Bat Salivary Plasminogen Activator (Desmoteplase) Inhibits Tissue-Type Plasminogen Activator-Induced Potentiation of Excitotoxic Injury Stroke, June 1, 2005; 36(6): 1241 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yepes, S. A.N. Brown, E. G. Moore, E. P. Smith, D. A. Lawrence, and J. A. Winkles A Soluble Fn14-Fc Decoy Receptor Reduces Infarct Volume in a Murine Model of Cerebral Ischemia Am. J. Pathol., February 1, 2005; 166(2): 511 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fernandez-Monreal, J. P. Lopez-Atalaya, K. Benchenane, M. Cacquevel, F. Dulin, J.-P. Le Caer, J. Rossier, A.-C. Jarrige, E. T. MacKenzie, N. Colloc'h, et al. Arginine 260 of the Amino-terminal Domain of NR1 Subunit Is Critical for Tissue-type Plasminogen Activator-mediated Enhancement of N-Methyl-D-aspartate Receptor Signaling J. Biol. Chem., December 3, 2004; 279(49): 50850 - 50856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yepes and D. A. Lawrence New Functions for an Old Enzyme: Nonhemostatic Roles for Tissue-Type Plasminogen Activator in the Central Nervous System Experimental Biology and Medicine, December 1, 2004; 229(11): 1097 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Suzuki, F. Chen, Y. Ni, G. Marchal, D. Collen, and N. Nagai Microplasmin Reduces Ischemic Brain Damage and Improves Neurological Function in a Rat Stroke Model Monitored With MRI Stroke, October 1, 2004; 35(10): 2402 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.N. Atochin, J.C. Murciano, Y. Gursoy-Ozdemir, T. Krasik, F. Noda, C. Ayata, A.K. Dunn, M.A. Moskowitz, P.L. Huang, and V.R. Muzykantov Mouse Model of Microembolic Stroke and Reperfusion Stroke, September 1, 2004; 35(9): 2177 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-Q. Zhao, Y. Ikeda, H. Ihara, T. Urano, W. Fan, S. Mikawa, Y. Suzuki, K. Kondo, K. Sato, N. Nagai, et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice Blood, April 1, 2004; 103(7): 2610 - 2616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nassar, S.'e. Akkawi, A. Shina, A. Haj-Yehia, K. Bdeir, M. Tarshis, S. N. Heyman, and A. A.-R. Higazi In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone Blood, February 1, 2004; 103(3): 897 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hoekstra, J. M. Geleijnse, C. Kluft, E. J. Giltay, F. J. Kok, and E. G. Schouten 4G/4G Genotype of PAI-1 Gene Is Associated With Reduced Risk of Stroke in Elderly Stroke, December 1, 2003; 34(12): 2822 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Melchor, R. Pawlak, and S. Strickland The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-{beta} (A{beta}) Degradation and Inhibits A{beta}-Induced Neurodegeneration J. Neurosci., October 1, 2003; 23(26): 8867 - 8871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Conway, F. Zwerts, V. Van Eygen, A. DeVriese, N. Nagai, W. Luo, and D. Collen Survivin-Dependent Angiogenesis in Ischemic Brain: Molecular Mechanisms of Hypoxia-Induced Up-Regulation Am. J. Pathol., September 1, 2003; 163(3): 935 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dai, H. Guan, L. Liu, S. Little, G. McFadden, S. Vaziri, H. Cao, I. A. Ivanova, L. Bocksch, and A. Lucas Serp-1, a Viral Anti-inflammatory Serpin, Regulates Cellular Serine Proteinase and Serpin Responses to Vascular Injury J. Biol. Chem., May 9, 2003; 278(20): 18563 - 18572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Liberatore, A. Samson, C. Bladin, W.-D. Schleuning, and R. L. Medcalf Vampire Bat Salivary Plasminogen Activator (Desmoteplase): A Unique Fibrinolytic Enzyme That Does Not Promote Neurodegeneration Stroke, February 1, 2003; 34(2): 537 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lapchak, D. M. Araujo, S. Pakola, D. Song, J. Wei, and J. A. Zivin Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits Stroke, September 1, 2002; 33(9): 2279 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, L. Zhang, M. Yepes, Q. Jiang, Q. Li, P. Arniego, T. A. Coleman, D. A. Lawrence, and M. Chopp Adjuvant Treatment With Neuroserpin Increases the Therapeutic Window for Tissue-Type Plasminogen Activator Administration in a Rat Model of Embolic Stroke Circulation, August 6, 2002; 106(6): 740 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mataga, N. Nagai, and T. K. Hensch Permissive proteolytic activity for visual cortical plasticity PNAS, May 28, 2002; 99(11): 7717 - 7721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Xue and M. R. Del Bigio Acute Tissue Damage After Injections of Thrombin and Plasmin into Rat Striatum Stroke, September 1, 2001; 32(9): 2164 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hosomi, J. Lucero, J. H. Heo, J. A. Koziol, B. R. Copeland, and G. J. del Zoppo Rapid Differential Endogenous Plasminogen Activator Expression After Acute Middle Cerebral Artery Occlusion Stroke, June 1, 2001; 32(6): 1341 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nagai, M. De Mol, B. Van Hoef, M. Verstreken, and D. Collen Depletion of circulating {alpha}2-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization Blood, May 15, 2001; 97(10): 3086 - 3092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Car and V. M. Eng Special Considerations in the Evaluation of the Hematology and Hemostasis of Mutant Mice Vet. Pathol., January 1, 2001; 38(1): 20 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yepes, M. Sandkvist, M. K. K. Wong, T. A. Coleman, E. Smith, S. L. Cohan, and D. A. Lawrence Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis Blood, July 15, 2000; 96(2): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Akassoglou, K. W. Kombrinck, J. L. Degen, and S. Strickland Tissue Plasminogen Activator-mediated Fibrinolysis Protects Against Axonal Degeneration and Demyelination after Sciatic Nerve Injury J. Cell Biol., May 29, 2000; 149(5): 1157 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nagai, I. Vanlinthout, and D. Collen Comparative Effects of Tissue Plasminogen Activator, Streptokinase, and Staphylokinase on Cerebral Ischemic Infarction and Pulmonary Clot Lysis in Hamster Models Circulation, December 21, 1999; 100(25): 2541 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Ginsberg On Ischemic Brain Injury in Genetically Altered Mice Arterioscler. Thromb. Vasc. Biol., November 1, 1999; 19(11): 2581 - 2583. [Full Text] [PDF]
|
|